PFM Health Sciences’s Ovintiv OVV Stock Holding History

PFM Health Sciences’s Portfolio OVV Stock Details OVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-297,587	Closed	-$17.5M	–	114
2016 Q4	$17.5M	Buy	+297,587	New	+$17M	0.49%	62

Other funds holding OVV

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

CCM

Causeway Capital Management Los Angeles, California $8.15B AUM 29.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

SCM

Steadfast Capital Management New York $2.92B AUM 26.34% 1-Year Est. Return

PFM Health Sciences's OVV Position: Q1 2017 in Review

PFM Health Sciences sold out of Ovintiv (OVV) in Q1 2017, closing a stake of 297,587 shares — an estimated $17.5M sold.

PFM Health Sciences first reported a position in OVV in Q4 2016 and held it in 1 quarter. The position peaked at $17.5M in Q4 2016. 316 funds tracked by Wall St. Rank hold OVV as of Q1 2017.

PFM Health Sciences reported no remaining Ovintiv position as of Q1 2017 after selling out during the quarter.
PFM Health Sciences sold 297,587 Ovintiv shares in Q1 2017, an estimated $17.5M.
PFM Health Sciences first reported a position in Ovintiv in Q4 2016 and held it in 1 quarter.
PFM Health Sciences's Ovintiv position peaked at $17.5M in Q4 2016.
316 funds tracked by Wall St. Rank held Ovintiv as of Q1 2017.

Based on PFM Health Sciences's 13F filing for Q1 2017, filed 15 May 2017.